" class="no-js "lang="en-US"> Mathai Mammen Joins FogPharma as Chairman, President & CEO
Monday, June 10, 2024

Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer

FogPharma, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced that Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer. Dr. Mathai Mammen brings significant global R&D and corporate leadership experience to FogPharma, having most recently served as executive vice president, pharmaceuticals, R&D, at Johnson & Johnson. Prior to that, Dr. Mammen served in senior R&D roles at Merck, Inc., having begun his career as founder and head of R&D at Theravance, Inc. Dr. Mammen will serve as an advisor to FogPharma beginning immediately and will assume his position as chairman, president and chief executive officer in June 2023. FogPharma founder Gregory Verdine, Ph.D., will transition from his current role as chairman and chief executive officer to vice chairman on the company’s board of directors.

“Mathai is a world-renowned innovator in drug discovery, development and company building who has created great teams, businesses and numerous important medicines over 25 years in small and large pharma. He brings this wealth of experience to FogPharma and we are thrilled to welcome him as our new chairman, president and chief executive officer,” said Dr. Verdine. “I am extremely excited to collaborate with Mathai as he takes over the reins of the company. This is the perfect time to transition FogPharma’s leadership as we prepare to advance our first development candidate, FOG-001, a first-and-only-in-class direct TCF-blocking β-catenin inhibitor, into clinical development for cancer in 2023.”

“I could not be more excited to join the talented FogPharma team to lead the company into its next chapter and beyond as we aim to create a highly modern and differentiated pharmaceutical company,” said Dr. Mathai Mammen. “FogPharma is based originally on ground-breaking drug discovery technology invented by Greg Verdine and his research team at Harvard University, and subsequently advanced and reduced to practice at FogPharma. The company’s Helicon™ therapeutics offer a general solution to otherwise undruggable protein-protein interactions inside a cell, much as monoclonal antibodies offer a general solution to protein-protein interactions outside a cell. This approach is an excellent foundation upon which to build a company that has the potential to make a profound impact on human health, and keep doing so indefinitely.”

Dr. Mammen was most recently on the Executive Committee at Johnson & Johnson, responsible for the pharmaceutical R&D organization, and spearheaded a significant evolution of Janssen’s R&D, one of the largest R&D organizations in the world. He was a key leader that shaped and drove Johnson & Johnson’s bold foray into COVID vaccines and helped drive Janssen’s substantial growth to become one of the top pharmaceutical companies globally. He led his team to global approvals of eight new medicines including Tremfya™, Darzalex Faspro™, Balversa™, Carvykti™, Rybrevant™, Ponvory™, Spravato™ and Tecvayli™, with many additional global approvals for expanded indications of marketed products. A central pillar to the strategy was data science, coupling recent revolutionary advances in data, compute and algorithmic approaches to every aspect of discovering and developing medicines. Under his leadership, Janssen R&D executed 40+ acquisitions and licenses and 350+ strategic partnerships and collaborations.

Dr. Mammen has authored more than 150 peer-reviewed journal publications, posters and patents. He received his M.D. from the Harvard Medical School and Massachusetts Institute of Technology HST program and a Ph.D. in chemistry from Harvard University.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more